Volume 42, number 3: Azithromycin-Resistant Syphilis Infection: San Francisco, California, 2000-2004
4th Jan 2006, 23:27 GMT
Background. The incidence of syphilis has been increasing in the United States since reaching a nadir in 2000. Several clinical trials have demonstrated that treatment with oral azithromycin may be useful for syphilis control. After reports of azithromycin treatment failures in San Francisco, we investigated the clinical and epidemiologic characteristics of patients with syphilis due to azithromycin-resistant Treponema pallidum infection. Methods. We reviewed city-wide case reports and conducted molecular screening for patients seen at the San Francisco metropolitan STD clinic (San Francisco City Clinic) to identify patients who did not respond to azithromycin treatment for syphilis or who were infected with azithromycin-resistant T. pallidum. We conducted an epidemiologic investigation and retrospective case-control study to identify risk factors for acquiring syphilis due to azithromycin-resistant T. pallidum. Results. From January 2000 through December 2004, molecular screening of 124 samples identified 46 azithromycin-resistant T. pallidum isolates and 72 wild-type T. pallidum isolates. Six instances of treatment failure were identified through record review. In total, we identified 52 case patients (one of whom had 2 episodes) and 72 control patients. All case patients were male and either gay or bisexual, and 31% (16 of 52) were infected with human immunodeficiency virus. Investigation of patient-partner links and a retrospective case-control study did not reveal a sexual network or demographic differences between cases and controls. However, 7 case patients had recently used azithromycin, compared with 1 control patient. Surveillance data demonstrated that azithromycin-resistant T. pallidum prevalence increased from 0% in 2000 to 56% in 2004 among syphilis cases observed at the San Francisco City Clinic. Conclusions. Azithromycin-resistant T. pallidum is widespread in San Francisco. We recommend against using azithromycin for the management of syphilis in communities where macrolide-resistant T. pallidum is present and recommend active surveillance for resistance in sites where azithromycin is used.
Volume 42, number 3: Azithromycin-Resistant Syphilis Infection: San Francisco, California, 2000-2004 related news:
- California News Tech Announces Licensing Agreement With InvestorIdeas.com — DBusiness News - San Francisco
- Volume 42, number 3: Secondary Pulmonary Syphilis: Report of A Likely Case and Literature Review — Clin Infect Dis Latest Issue
- San Francisco Giants' J.T. Snow, left, lets out a yell after ... — Most Emailed Photos - Sports on Yahoo! News Photos
- Athens 2004 Summer Games — Latest San Francisco, California Stories (RSS .91)
- 78% Californians Believe Comprehensive Sex Education Programs Should Be Taught In Public Schools, Survey Says — Medical News Today RSS/XML Feed
- San Ramon Kids Left Home Alone — Latest San Francisco, California Stories (RSS .91)
- San Anselmo Assesses Damage — Latest San Francisco, California Stories (RSS .91)
- CytoDyn Picks San Francisco for Next Trial — Financial News USA (OTC: FNWU)
- Predictions for MacWorld San Francisco? — The Apple Blog
- Conference explores use of microbes in nanotechnology — EurekAlert! - Chemistry, Physics and Materials Sciences
Latest news from Clin Infect Dis Latest Issue:
- Volume 43, number S4: Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
- Volume 43, number S4: Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
- Volume 43, number S4: The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
- Volume 43, number S4: A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
- Volume 43, number S4: Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States
- Volume 43, number S4: Buprenorphine Use: The International Experience
- Volume 43, number S4: Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
- Volume 43, number S4: Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care